Vertex Pharmaceuticals Reports Q1 Earnings Beat and Provides Full-Year Guidance
Vertex Pharmaceuticals (VRTX) reported first-quarter results that exceeded Wall Street expectations, with adjusted EPS of $4.47 against a forecast of $4.23 and revenue reaching $2.99 billion versus an expected $2.98 billion. The company provided full-year revenue guidance between $13 billion to $13.1 billion.
Topics: analyst expectations biotech pharmaceuticals stock performance